2136P ASP2138 monotherapy or in combination with pembrolizumab and mFOLFOX6 or with ramucirumab and paclitaxel in claudin 18 isoform 2 (CLDN18.2) + locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Phase I/Ib trial
Publication
, Conference
Dayyani, F; Strickler, JH; Hará, K; Kasi, A; Kitano, S; Mahalingam, D; Mitani, S; Shitara, K; Xu, R-H; Guseva, MV; Yang, J; Bhattacharya, S ...
Published in: Annals of Oncology
September 2025
Duke Scholars
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2025
Volume
36
Start / End Page
S1120 / S1120
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Dayyani, F., Strickler, J. H., Hará, K., Kasi, A., Kitano, S., Mahalingam, D., … Klempner, S. J. (2025). 2136P ASP2138 monotherapy or in combination with pembrolizumab and mFOLFOX6 or with ramucirumab and paclitaxel in claudin 18 isoform 2 (CLDN18.2) + locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Phase I/Ib trial. In Annals of Oncology (Vol. 36, pp. S1120–S1120). Elsevier BV. https://doi.org/10.1016/j.annonc.2025.08.2755
Dayyani, F., J. H. Strickler, K. Hará, A. Kasi, S. Kitano, D. Mahalingam, S. Mitani, et al. “2136P ASP2138 monotherapy or in combination with pembrolizumab and mFOLFOX6 or with ramucirumab and paclitaxel in claudin 18 isoform 2 (CLDN18.2) + locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Phase I/Ib trial.” In Annals of Oncology, 36:S1120–S1120. Elsevier BV, 2025. https://doi.org/10.1016/j.annonc.2025.08.2755.
Dayyani F, Strickler JH, Hará K, Kasi A, Kitano S, Mahalingam D, et al. 2136P ASP2138 monotherapy or in combination with pembrolizumab and mFOLFOX6 or with ramucirumab and paclitaxel in claudin 18 isoform 2 (CLDN18.2) + locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Phase I/Ib trial. In: Annals of Oncology. Elsevier BV; 2025. p. S1120–S1120.
Dayyani, F., et al. “2136P ASP2138 monotherapy or in combination with pembrolizumab and mFOLFOX6 or with ramucirumab and paclitaxel in claudin 18 isoform 2 (CLDN18.2) + locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Phase I/Ib trial.” Annals of Oncology, vol. 36, Elsevier BV, 2025, pp. S1120–S1120. Crossref, doi:10.1016/j.annonc.2025.08.2755.
Dayyani F, Strickler JH, Hará K, Kasi A, Kitano S, Mahalingam D, Mitani S, Shitara K, Xu R-H, Guseva MV, Yang J, Bhattacharya S, Weddell J, Ma J, Souders N, Telaranta-Keerie A, Quarshie L, Klempner SJ. 2136P ASP2138 monotherapy or in combination with pembrolizumab and mFOLFOX6 or with ramucirumab and paclitaxel in claudin 18 isoform 2 (CLDN18.2) + locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Phase I/Ib trial. Annals of Oncology. Elsevier BV; 2025. p. S1120–S1120.
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2025
Volume
36
Start / End Page
S1120 / S1120
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences